Ipilimumab — CTLA-4 Immune Checkpoint Inhibitor in Cancer Treatment
July 06, 2026
Ipilimumab inhibits CTLA-4, amplifying the anti-cancer immune response. Commonly combined with Nivolumab for optimal outcomes.
## CTLA-4 Inhibition Mechanism
Ipilimumab is a monoclonal antibody targeting CTLA-4 — a regulatory "brake" receptor on T cells. By blocking CTLA-4, Ipilimumab enhances and prolongs anti-tumour T cell activity. It was the first approved immune checkpoint inhibitor for melanoma.
## Combination with Nivolumab
The Ipilimumab + Nivolumab combination (doublet immunotherapy) is now standard in advanced melanoma, high PD-L1 lung cancer, renal cell carcinoma and hepatocellular carcinoma. Response rates exceed monotherapy but immune-related adverse events also increase — close monitoring is required.
## In China
Ipilimumab + Nivolumab doublet immunotherapy is applied at HYGEIA and GoBroad for advanced melanoma, lung and renal cancer.
## Disclaimer
Information is for reference only. The physician determines the protocol and manages adverse events.